B. Cheson and J. Leonard, Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma, New England Journal of Medicine, vol.359, issue.6, pp.613-639, 2008.
DOI : 10.1056/NEJMra0708875

D. Thomas, O. Brien, S. Kantarjian, and H. , Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia, Hematology/Oncology Clinics of North America, vol.23, issue.5, pp.949-71, 2009.
DOI : 10.1016/j.hoc.2009.07.005

W. Zhao, Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways, Leukemia, vol.32, issue.1, pp.13-21, 2010.
DOI : 10.1016/j.cellsig.2009.03.009

N. Ferrara, H. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nature Medicine, vol.9, issue.6, pp.669-76, 2003.
DOI : 10.1038/nm0603-669

A. Grothey and E. Galanis, Targeting angiogenesis: progress with anti-VEGF treatment with large molecules, Nature Reviews Clinical Oncology, vol.26, issue.9, pp.507-525, 2009.
DOI : 10.1038/nrclinonc.2009.110

I. Avramis, E. Panosyan, F. Dorey, J. Holcenberg, and V. Avramis, Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962, Clinical Cancer Research, vol.12, issue.23, pp.6978-84, 2006.
DOI : 10.1158/1078-0432.CCR-06-1140

S. Paydas, M. Ergin, S. Erdogan, and G. Seydaoglu, Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas, Leukemia Research, vol.32, issue.9, pp.1424-1454, 2008.
DOI : 10.1016/j.leukres.2008.01.008

W. Zhao, S. Mourah, N. Mounier, C. Leboeuf, M. Daneshpouy et al., Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression, Laboratory Investigation, vol.103, issue.11, pp.1512-1521, 2004.
DOI : 10.1038/labinvest.3700145

K. Tei, N. Kawakami-kimura, O. Taguchi, K. Kumamoto, S. Higashiyama et al., Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats, Cancer Res, vol.62, issue.21, pp.6289-96, 2002.

J. Millan, L. Hewlett, M. Glyn, D. Toomre, P. Clark et al., Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains, Nature Cell Biology, vol.280, issue.2, pp.113-136, 2006.
DOI : 10.1083/jcb.70.3.608

A. Boyd, S. Dunn, J. Fecondo, J. Culvenor, U. Duhrsen et al., Regulation of expression of a human intercellular adhesion molecule (ICAM-1) during lymphohematopoietic differentiation, Blood, vol.73, issue.7, pp.1896-903, 1989.

K. Brooks, E. Coleman, and E. Vitetta, The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines, International Journal of Cancer, vol.12, issue.10, pp.2438-2483, 2008.
DOI : 10.1002/ijc.23793

J. Karp, I. Gojo, R. Pili, C. Gocke, J. Greer et al., Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-??-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab, Clinical Cancer Research, vol.10, issue.11, pp.3577-85, 2004.
DOI : 10.1158/1078-0432.CCR-03-0627

A. Bujanda and D. , Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab, Annals of Oncology, vol.19, issue.2, pp.396-403, 2008.
DOI : 10.1093/annonc/mdm579

N. Schicher, V. Paulitschke, A. Swoboda, R. Kunstfeld, R. Loewe et al., Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma, Clinical Cancer Research, vol.15, issue.10, pp.3495-502, 2009.
DOI : 10.1158/1078-0432.CCR-08-2407

A. Zhu, N. Holalkere, A. Muzikansky, K. Horgan, and D. Sahani, Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma, The Oncologist, vol.13, issue.2, pp.120-125, 2008.
DOI : 10.1634/theoncologist.2007-0174

R. Kerbel and J. Folkman, Clinical translation of angiogenesis inhibitors, Nature Reviews Cancer, vol.17, issue.10, pp.727-766, 2002.
DOI : 10.1038/nrc905

H. Gerber and N. Ferrara, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies, Cancer Res, vol.65, issue.3, pp.671-80, 2005.

P. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, Nature Medicine, vol.96, issue.8, pp.895-904, 2006.
DOI : 10.1038/nm1469

O. Haddad, R. Chotard-ghodsnia, C. Verdier, and A. Duperray, Tumor cell/endothelial cell tight contact upregulates endothelial adhesion molecule expression mediated by NF??B: Differential role of the shear stress, Experimental Cell Research, vol.316, issue.4, pp.615-641, 2010.
DOI : 10.1016/j.yexcr.2009.11.015

V. Levina, Y. Su, B. Nolen, X. Liu, Y. Gordin et al., Chemotherapeutic drugs and human tumor cells cytokine network, International Journal of Cancer, vol.67, issue.9, pp.2031-2071, 2008.
DOI : 10.1002/ijc.23732

S. Lee, X. Xu, Y. Lim, P. Iau, N. Sukri et al., Chemotherapy-induced tumor gene expression changes in human breast cancers, Pharmacogenetics and Genomics, vol.19, issue.3, pp.181-92, 2009.
DOI : 10.1097/FPC.0b013e32831ebb5d

J. Zhang, T. Silva, T. Yarovinsky, T. Manes, S. Tavakoli et al., VEGF Blockade Inhibits Lymphocyte Recruitment and Ameliorates Immune-Mediated Vascular Remodeling, Circulation Research, vol.107, issue.3, pp.408-425, 2010.
DOI : 10.1161/CIRCRESAHA.109.210963